The Key to Our Success: Super Transdermal Absorption Technique

At GcMAFplus®, our breakthrough lies in the development of a proprietary Super Transdermal Absorption Technique — a delivery system designed to achieve deep skin penetration and efficient immune activation.

Unlike conventional methods, our transdermal GcMAF formulation is engineered to cross the skin barrier and reach the dermal and lymphatic layers, where it activates macrophages — the immune system’s first line of defense. Once activated, these macrophages help identify and eliminate pathogens, abnormal cells, and support tissue repair.

Our lipophilic, bioavailable formula enables lymphatic transport, allowing GcMAF to circulate through lymph nodes and immune-rich tissues, thereby facilitating systemic immune support. This sustained delivery enhances the immune system’s ability to identify and respond to health threats — from chronic inflammation to degenerative conditions.

All GcMAFplus® products are manufactured in a state-of-the-art, GMP ISO22716-certified laboratory, ensuring the highest standards of safety, purity, and potency. Each batch is rigorously tested for sterility, bioactivity, and consistency.

Our advanced delivery system and clinical-grade GcMAF have earned global recognition from healthcare professionals and patients alike. This innovation in transdermal delivery provides a non-invasive, reliable means of immune modulation, particularly for those seeking natural support in the management of immune dysfunction, inflammation, or complex chronic illness.

By enhancing macrophage function through direct lymphatic access, GcMAFplus® empowers the body’s innate repair and defense mechanisms. The sustained release via transdermal application ensures ongoing support for immune resilience and overall health.

Transdermal GcMAF Delivery: Efficacy and Advantages

Transdermal delivery of GcMAF offers several benefits over traditional administration routes:

• Enhanced Bioavailability: By bypassing the gastrointestinal tract, transdermal application avoids degradation by stomach acids, ensuring more GcMAF reaches systemic circulation.

• Sustained Release: Transdermal systems can provide a controlled release of GcMAF, maintaining therapeutic levels over extended periods.

• Improved Patient Compliance: Non-invasive and painless, transdermal application is more acceptable to patients, leading to better adherence to treatment regimens.

Studies have demonstrated the effectiveness of transdermal drug delivery systems in achieving consistent plasma concentrations and therapeutic outcomes.

Scientific Innovation in Immune Support

At GcMAFplus®, our transdermal and sublingual formulations are designed to deliver purified, bioidentical GcMAF directly to the immune system via the skin or mucous membranes. Once absorbed, GcMAF activates macrophages — the body’s primary immune sentinels.

Emerging research highlights the importance of a gene called ZEB2, a master transcription factor expressed in activated macrophages, which plays a critical role in reprogramming the immune system to target abnormal and tumor-associated cells.

By facilitating macrophage activation through our advanced, non-fermentation GcMAF production and Super Transdermal Absorption Technique, GcMAFplus® supports the natural immune cascade that leads to ZEB2 expression and improved immune coordination. This next-generation approach enhances immune readiness and helps maintain tissue health across a wide range of conditions.

Our advanced delivery system ensures that GcMAF penetrates the skin barrier efficiently, reaching underlying tissues and the lymphatic system, where it can exert its immunomodulatory effects.

ZEB2: A Master Regulator of Macrophage Identity

Recent research has identified ZEB2 (Zinc finger E-box-binding homeobox 2) as a critical transcription factor essential for maintaining the tissue-specific identity and function of macrophages. Loss of ZEB2 leads to the disappearance of macrophages from tissues, underscoring its pivotal role in immune homeostasis.

Furthermore, ZEB2 has been shown to control tumor-associated macrophage programs. Targeting ZEB2 can epigenetically reprogram these macrophages, enhancing T cell responses and promoting anti-tumor immunity.

Integrating ZEB2 and Transdermal GcMAF in GcMAFplus®

At GcMAFplus®, our proprietary transdermal formulations are designed to activate macrophages effectively. By leveraging the role of ZEB2 in maintaining macrophage identity, our GcMAF products aim to support the immune system’s natural defense mechanisms.